Relmada Therapeutics Inc (RLMD)

$3.80 -0.03 (-0.78%)
Market Cap 260.34M
Revenue (ttm) 0.00
Net Income (ttm) -79.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 601,500
Avg Vol 780,104
Day's Range N/A - N/A
Shares Out 73.33M
Stochastic %K 28%
Beta 0.77
Analysts Strong Sell
Price Target $9.00

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 629 1376
Address:
2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States
Main_Street_Risks
Main_Street_Risks Jan. 27 at 3:31 AM
$RLMD This SP still seems odd. I think it should retrace....but I also wonder if they are going to sell soon. I don't think they can really do this thing on their own. It really should be scooped up.
0 · Reply
teaman60
teaman60 Jan. 23 at 9:15 PM
$RLMD I hate upgrades, it means the stock price can only go lower. Please investment house, stay away
0 · Reply
notreload_ai
notreload_ai Jan. 23 at 1:32 PM
Leerink starts coverage on $RLMD , upgrades the stock to Outperform, and highlights strong potential for its bladder cancer program NDV-01. https://notreload.xyz/leerink-upgrades-relmada-therapeutics-rlmd-with-8-price-target/
0 · Reply
RiskCPremium
RiskCPremium Jan. 17 at 5:25 PM
$RLMD https://clinicaltrials.gov/study/NCT07342517
1 · Reply
teaman60
teaman60 Jan. 16 at 2:36 PM
$RLMD this is in big trouble
1 · Reply
VikaDelic
VikaDelic Jan. 15 at 7:03 PM
$RLMD Teamaam in a few weeks. Poor guy has been short since 2 and can’t even spell psychedelic
2 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 12:42 PM
$RLMD Current Stock Price: $3.84 Contracts to trade: $5 RLMD Jan 16 2026 Call Entry: $0.05 Exit: $0.06 ROI: 28% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
VikaDelic
VikaDelic Jan. 14 at 8:12 PM
$RLMD insider buys, fastest FDA path just confirmed for onc asset, psychedelic wt loss data before long. ⏰
0 · Reply
teaman60
teaman60 Jan. 14 at 5:49 PM
$RLMD this has almost no upside unless there is a buyout of their science.
0 · Reply
teaman60
teaman60 Jan. 14 at 3:24 AM
$RLMD Heading into the high 2s by Feb. Company burning cash with zero revenues. Not a chance their drug ever gets to the market without a buyout
0 · Reply
Latest News on RLMD
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Jan 12, 2026, 7:00 AM EST - 22 days ago

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Dec 3, 2025, 7:30 AM EST - 2 months ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:21 PM EST - 2 months ago

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 13, 2025, 4:01 PM EST - 2 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 7, 2025, 7:30 AM EST - 3 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:09 AM EST - 3 months ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Nov 4, 2025, 7:01 AM EST - 3 months ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Oct 7, 2025, 7:30 AM EDT - 4 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 16, 2025, 9:00 AM EDT - 5 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Relmada Issues Mid-Year CEO Letter to Shareholders

Sep 10, 2025, 7:15 AM EDT - 5 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 1:55 PM EDT - 6 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Aug 7, 2025, 4:05 PM EDT - 6 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 31, 2025, 7:00 AM EDT - 6 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 15, 2025, 8:00 AM EDT - 7 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jul 9, 2025, 8:00 AM EDT - 7 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Jun 17, 2025, 7:00 AM EDT - 8 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:02 PM EDT - 9 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:01 PM EDT - 9 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 8, 2025, 7:30 AM EDT - 9 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 28, 2025, 1:38 PM EDT - 10 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 10 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 24, 2025, 8:00 AM EDT - 10 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 14, 2025, 7:30 AM EDT - 10 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:07 PM EDT - 11 months ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 27, 2025, 4:05 PM EDT - 11 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 26, 2025, 9:00 AM EDT - 11 months ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Mar 25, 2025, 7:30 AM EDT - 11 months ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Feb 6, 2025, 7:30 AM EST - 1 year ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 2:02 PM EST - 1 year ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 10, 2024, 9:39 AM EST - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Jul 19, 2024, 5:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Jul 18, 2024, 5:15 PM EDT - 1 year ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

Jul 17, 2024, 3:30 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Jul 16, 2024, 3:45 PM EDT - 1 year ago

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Jul 15, 2024, 3:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

Jul 13, 2024, 7:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

Main_Street_Risks
Main_Street_Risks Jan. 27 at 3:31 AM
$RLMD This SP still seems odd. I think it should retrace....but I also wonder if they are going to sell soon. I don't think they can really do this thing on their own. It really should be scooped up.
0 · Reply
teaman60
teaman60 Jan. 23 at 9:15 PM
$RLMD I hate upgrades, it means the stock price can only go lower. Please investment house, stay away
0 · Reply
notreload_ai
notreload_ai Jan. 23 at 1:32 PM
Leerink starts coverage on $RLMD , upgrades the stock to Outperform, and highlights strong potential for its bladder cancer program NDV-01. https://notreload.xyz/leerink-upgrades-relmada-therapeutics-rlmd-with-8-price-target/
0 · Reply
RiskCPremium
RiskCPremium Jan. 17 at 5:25 PM
$RLMD https://clinicaltrials.gov/study/NCT07342517
1 · Reply
teaman60
teaman60 Jan. 16 at 2:36 PM
$RLMD this is in big trouble
1 · Reply
VikaDelic
VikaDelic Jan. 15 at 7:03 PM
$RLMD Teamaam in a few weeks. Poor guy has been short since 2 and can’t even spell psychedelic
2 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 12:42 PM
$RLMD Current Stock Price: $3.84 Contracts to trade: $5 RLMD Jan 16 2026 Call Entry: $0.05 Exit: $0.06 ROI: 28% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
VikaDelic
VikaDelic Jan. 14 at 8:12 PM
$RLMD insider buys, fastest FDA path just confirmed for onc asset, psychedelic wt loss data before long. ⏰
0 · Reply
teaman60
teaman60 Jan. 14 at 5:49 PM
$RLMD this has almost no upside unless there is a buyout of their science.
0 · Reply
teaman60
teaman60 Jan. 14 at 3:24 AM
$RLMD Heading into the high 2s by Feb. Company burning cash with zero revenues. Not a chance their drug ever gets to the market without a buyout
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jan. 13 at 5:24 PM
🚀 The Wildest Small-Caps Runners of 2025 While most eyes stayed on megacaps, these names delivered massive calendar-year gains, from triple-digit movers to near 20 baggers. 📊2025 Performance (Under 300M market cap) 1. $FIEE (FIE) 🟰 +1,950.00% 2. $DBGI (Digital Brands Group) 🟰 +1,112.70% 3. $RLMD (Relmada Therapeutics) 🟰 +871.24% 4. $XWIN.X (XMax) 🟰 +850.81% 5. $SOGP (Sound Group) 🟰 +847.42% 6. TII (Titan Mining) 🟰 +819.77% 7. DFDV (DeFi Development) 🟰 +797.93% 8. ZEPP (Zepp Health Corporation) 🟰 +665.20% 10. SLGL (Sol-Gel Technologies) 🟰 +467.09% 11. BLBX (Blackboxstocks) 🟰 +431.22% Now the focus shifts to 2026 and which names are worth watching as momentum resets.
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 12:35 PM
$RLMD 07:16 on Jan. 12 2026 Relmada Therapeutics Receives Written Feedback from FDA Regarding NDV-01 In Second-Line Refractory, High-Grade BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ #tradeideas
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 12:17 PM
$RLMD 07:16 on Jan. 12 2026 Relmada Therapeutics Receives Written Feedback from FDA Regarding NDV-01 In Second-Line Refractory, High-Grade BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ #tradeideas
0 · Reply
YGLD
YGLD Jan. 10 at 8:15 PM
Biotech Phase 3 Catalyst Watchlist - Ranked By Timing ⏱️ $SLS $GOSS $OCUL $RLMD
0 · Reply
teaman60
teaman60 Jan. 9 at 8:12 PM
$RLMD cash burn
0 · Reply
Icemanrush16
Icemanrush16 Jan. 9 at 4:48 PM
$AQST so a beat up BIO! I’m in $CORT $MREO $RLMD $ZBIO
0 · Reply
VikaDelic
VikaDelic Jan. 5 at 6:36 PM
$RLMD soon enough we find out why insiders won’t stop buying. Someone accumulated this nonstop for the last two months- final shakeout unfolding… they got Teabag working overtime! 🤣
1 · Reply
teaman60
teaman60 Jan. 5 at 5:47 PM
$RLMD Ugly
0 · Reply
teaman60
teaman60 Jan. 3 at 7:05 PM
$RLMD Jan going to bring this into the $2S, no way to avoid it. The cash burn is a killer
0 · Reply
garygb
garygb Jan. 3 at 6:45 PM
$RLMD Patience
0 · Reply
makingitnow
makingitnow Jan. 3 at 3:33 AM
$RLMD stopped out today at $4.30 from 1.74. may revisit
0 · Reply
teaman60
teaman60 Jan. 2 at 7:02 PM
$RLMD Stay away, they can't get this over the finish line
0 · Reply